Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals

Article Article scientifique Article Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals eng 2022-02-10 2022-02-10 author Portillo Vera author Fedeli Chiara author Ustero Alonso Pilar 953554 author Petignat Ianis 824359 author Mereles Costa Ellen Cristina 814711 author Sulstarova Adi 833782 author Jaksic Cyril 697773 author Yerly Ferrillo Sabine 23752 author Calmy Alexandra 0000-0002-1137-6826 41032 820126 10.3389/fimmu.2021.820126 35222357 1664-3224 PMC8866244 https://www.frontiersin.org/articles/10.3389/fimmu.2021.820126/full This study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273 or BNT162b2. Both anti-N and anti-S1-receptor binding domain (RBD) antibodies were measured together with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2 (M2) and 6 (M6) months later. A total of 131 individuals (median age: 54 years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl [IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0]) were included. All participants were positive for anti-RBD antibodies at 30 days, 60 days and 6 months after the first dose, with no statistical difference between those with HIV-1 RNA below or >20 copies/ml. HIV-1 RNA data were collected for 128 patients at baseline and 30 days after the first dose; for 124 individuals, 30 days after the second dose; and for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128 had detectable HIV-1 RNA (>20 copies/ml) at M0, 13/128 (10.2%) at M1 (among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which 5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse effects were reported. All participants elicited antibodies after two doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels over a 6-month period. HIV PLWH SARS-CoV-2 Serology Vaccination 2019-nCoV Vaccine mRNA-1273 / immunology Adult Aged Antibodies, Viral / blood Antibody Formation BNT162 Vaccine / immunology CD4-Positive T-Lymphocytes / immunology COVID-19 / immunology Coronavirus Nucleocapsid Proteins / immunology Female HIV Infections / immunology HIV-1 / physiology Humans Immunity, Heterologous Male Middle Aged Phosphoproteins / immunology RNA, Viral / analysis SARS-CoV-2 / physiology Spike Glycoprotein, Coronavirus / immunology Vaccination Dewey 616 Dewey 618 Geneva University Hospitals Projet de recherche et développement (PRD) 2021-00491 56 Département de médecine 221 217 Centre de recherche clinique 201 false 400 Groupe Laurent Kaiser (virologie clinique) 668 587 VIH/SIDA 930 88 Epidémiologie clinique et biostatistique 115 Frontiers in immunology 12 1a6db3c1-84e8-4476-85b6-d2edabbc8889 Article (Published version) Public Article-scientifique-from-unpaywall.pdf 1936304 application/pdf CC BY-4.0 openAccess Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Centre de recherche clinique

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals	Frontiers in immunology			2022	211	66

Archive ouverte UNIGE

Mereles Costa, Ellen Cristina